German students awarded 2025 Stockholm Junior Water Prize for flood warning innovation
26.8.2025 23:00:00 CEST | Business Wire | Press Release
Niklas Ruf and Jana Spiller from Germany received the prestigious Stockholm Junior Water Prize 2025 for their work on developing a scalable flood warning system for small streams. H.R.H. Crown Princess Victoria of Sweden presented the winners with their award during a ceremony at Stockholm City Hall as part of World Water Week in Stockholm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250826809663/en/
Niklas Ruf and Jana Spiller from Germany received the 2025 Stockholm Junior Water Prize for their scalable flood warning system for small streams. The award was presented by H.R.H. Crown Princess Victoria of Sweden at Stockholm City Hall during World Water Week. Image courtesy of Jonas Borg.
Flooding is an increasing concern worldwide, with more frequent and larger floods affecting communities. Yet on smaller streams, real-time data is often lacking, limiting the possibility of early warnings. Over four years of work, Ruf and Spiller created a network of sensors linked to an app that provides live alerts to both experts and the public. Their system is already being scaled up across their region in consultation with multiple partners.
The Jury noted that the project “addresses a critical challenge we are seeing around the globe: more frequent and bigger floods. Yet on smaller streams, we often lack the data needed to provide real-time warnings. The students have not only built a functioning system and an app that notifies experts and the public, they are already working to scale this system across their region in consultation with numerous partners.”
When asked how it felt to win, Niklas Ruf admitted: “I didn’t expect it at all. There were so many really good projects. I thought we were just here to have a good time and then go back home.”
Jana Spiller added: “Every project here is just amazing. Some were in areas like chemistry and biology that I didn’t even fully understand, but they were so impressive. That’s why it was such a big surprise for us.”
On what they hope decision-makers and industry leaders will take away from their work, the team reflected: “Of course, what we are doing is building something to tackle the consequences of climate change. But the ideal solution would be if there were no climate change to begin with.”
Diploma of Excellence – Türkiye
The Diploma of Excellence was awarded to Kagan Mehmet Ozkok from Türkiye for pioneering work that combines AI and water efficiency. By training artificial intelligence on the sound of leaking water, Ozkok built and deployed two prototypes to detect leaks in public spaces. Tested under real conditions, the prototypes demonstrated significant water savings and are now being developed further in collaboration with local government for possible city-wide implementation.
The Jury stated: “This year’s Diploma of Excellence recognizes how data, AI and action come together. Training AI based on the sound of leaking water, this student has demonstrated a powerful and practical approach to tackling urban water loss.”
People’s Choice Award – United Kingdom
The People’s Choice Award, voted on by the global public, went to Divyasri Kothapalli from the United Kingdom for her project Sun-based water distillation system.
This research project presents the development of a low-cost solar water distillation system designed to improve access to clean drinking water in off-grid and rural communities. Using a Fresnel lens to focus sunlight onto a metal boiling pot, the resulting steam passes through food-grade silicone tubing and condenses into clean water. The system operates without electricity, avoiding additional carbon emissions.
Kothapalli conducted three experiments where the independent variables included initial water volume, light intensity, and natural weather conditions. The system produced consistent yields even in moderate climates such as the UK, showing its promise for broader application.
“Innovation is paving the way to a more water-secure world, and the next generation is accelerating progress. The Stockholm Junior Water Prize competitors are an inspiring example of the ingenuity and passion young innovators bring to the table. On behalf of Xylem, I’d like to congratulate all those who took part in this year’s competition,” said Claudia Toussaint, Chief People and Sustainability Officer at Xylem.
“Xylem is proud to invest in the young innovators of the Stockholm Junior Water Prize. They are already shaping the future as the next generation of water problem-solvers. Together, we have the opportunity to empower communities everywhere to create a more water-secure world,” Toussaint added.
A year of flood-focused excellence
This year, both Water Prizes highlighted flooding: the Stockholm Junior Water Prize went to German students Niklas Ruf and Jana Spiller for their innovative flood warning system, while the Stockholm Water Prize will be awarded to Austrian professor Günter Blöschl, the world’s leading flood hydrologist. Together, their work underscores the urgency of addressing flood risks – from local innovations to global science.
Read more about the winning projects here:
- Stockholm Junior Water Prize 2025: Germany – Niklas Ruf and Jana Spiller
- Diploma of Excellence 2025: Türkiye – Kagan Mehmet Ozkok
- People’s Choice Award 2025: United Kingdom – Divyasri Kothapalli
About the Stockholm Junior Water Prize
The Stockholm Junior Water Prize is an international competition for students between the ages of 15 and 20, encouraging innovative solutions to major water challenges. Every year, thousands of young people from more than 40 countries take part, with the national winners competing in the global final in Stockholm.
The Stockholm Junior Water Prize has been organized annually since 1997. It is hosted by the Stockholm Water Foundation, with Xylem as Founding Partner.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250826809663/en/
Contacts
Christina Bergstrand
SENIOR COMMUNICATIONS MANAGER
Mobile: +46 72050612
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom